Search
Kathryn Doyle, a partner at Saul Ewing, will present during the Penn Medicine Commercialization Speaker Series. She will discuss the latest trends in Life Sciences intellectual property on November 17 from 12:00 - 1:00 p.m.
MAKING SENSE OF PRES. BIDEN’S CANNABIS REFORM STATEMENT – FDA’S ROLE IN SCHEDULING EVALUATION Jonathan Havens, Co-Chair of the firm's Cannabis Practice, will discuss President Biden’s recent cannabis reform announcement, its implications for various stakeholders, and FDA’s role in evaluating how...
Allison Burdette, associate at Saul Ewing, will be presenting to the Children's Hospital of Los Angeles on October 12, 2022. She will focus on the topics of insight into regulatory/insurance litigations around compliance matters (i.e., Anti-kickback, Physician Self-Referrals, HIPAA, False Claims...
Washington, D.C.’s (D.C. or the District) Alcoholic Beverage Regulation Administration (ABRA) is now accepting applications for three new alcohol licenses that were created by the Reopen Washington D.C. Alcoholic Beverage Regulation Administration Amendment Act of 2022. We detail each of these...
The U.S. Food and Drug Administration (FDA or the Agency) today published in the Federal Register a proposed rule that, if finalized, would update the standards that food products must meet in order to be labeled as “healthy.” Per FDA, the proposed rule would “align the definition of ‘healthy’ with...
ENERGY INNOVATION: HOW NATURAL GAS AND NEW ENERGY TECHNOLOGIES ARE SHAPING THE FUTURE OF PITTSBURGH INTERNATIONAL AIRPORT (NON-CLE) Jeffrey Letwin, a Counsel in the firm's Energy practice, will be speaking at the 13th Appalachia Energy Law Conference. His panel will consist of representatives from...
Saul Ewing LLP served as counsel to Marwin II, LLC, a wholly owned subsidiary of US Wind, Inc., in the application to the Maryland Public Service Commission for, and approval of, approximately 800 megawatts of Maryland Offshore Renewable Energy Credits ("ORECs"). The addition of the extra 800...
Charles M. Lizza and Sarah A. Sullivan of Saul Ewing’s Newark Office secured a precedent-setting victory in a patent infringement case in the Federal District Court for the District of New Jersey involving Janssen Pharmaceuticals, Inc.’s (“J&J”) and Mitsubishi Tanabe Pharma Corp.’s (“MTPC”)...